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Abstract Seizures are common in patients with gliomas,
and phenytoin (PHT) is frequently used to control tumor-
related seizures. PHT, however, has many undesirable side
effects (SEs) and drug interactions with glioma chemo-
therapy. Levetiracetam (LEV) is a newer antiepileptic drug
(AED) with fewer SEs and essentially no drug interactions.
We performed a pilot study testing the safety and feasi-
bility of switching patients from PHT to LEV monotherapy
for postoperative control of glioma-related seizures. Over a
13-month period, 29 patients were randomized in a 2:1
ratio to initiate LEV therapy within 24 h of surgery or to
continue PHT therapy. 6 month follow-up data were
available for 15 patients taking LEV and for 8 patients
taking PHT. In the LEV group, 13 patients (87%) were
seizure-free. In the PHT group, 6 patients (75%) were
seizure-free. Reported SEs at 6 months was as follows
(%LEV/%PHT group): dizziness (0/14), difﬁculty with
coordination (0/29), depression (7/14) lack of energy or
strength (20/43), insomnia (40/43), mood instability (7/0).
The pilot data presented here suggest that it is safe to
switch patients from PHT to LEV monotherapy following
craniotomy for supratentorial glioma. A large-scale, dou-
ble-blinded, randomized control trial of LEV versus PHT is
required to determine seizure control equivalence and
better assess differences in SEs.
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Introduction
At diagnosis, *20–40% of all brain tumor patients will
have had a seizure [1] that may result in morbidity and
decreased quality of life [2]. Thus, treatment with antiep-
ileptic drugs (AEDs) is clearly indicated for brain tumor
patients with preoperative tumor-related seizures [3–5].
Surgical treatment of brain tumors is also associated with a
high risk of postoperative seizures. Approximately, one-
third of patients have seizures after tumor resection [6–8],
and in the case of supratentorial craniotomy, 20%–50% of
patients have C1 seizure [9, 10].
Brain tumor patients who experience tumor-related
seizures are often placed on phenytoin (PHT) therapy.
Although there are no formal guidelines, it is common
practice to continue PHT after craniotomy in these patients.
However, PHT has many side effects (SEs) and undesirable
interactions with drugs used to treat brain tumors [1, 11–
14] which can complicate the pharmacological treatment of
these tumors.
Levetiracetam (LEV) is a newer AED that possesses a
different pharmacological proﬁle from that of PHT, with no
effects on liver enzymes and no known effect on the
kinetics of other medications [15, 16]. Furthermore, other
medications including enzyme-inducing AEDs have
essentially no effect on LEV pharmacokinetics [15, 17]. In
retrospective studies, LEV has been found to be effective
and well tolerated as add-on or monotherapy in patients
with either primary or metastatic brain tumors [18, 19].
Prospectively, LEV has been studied mostly as add-on
therapy for persistent tumor-related seizures [20, 21], and
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with few SEs.
Ideally, patients with brain tumor-related seizures would
achieve seizure control with an AED that does not nega-
tively interact with adjunctive chemotherapy and has few
SEs. However, PHT is still commonly used as a ﬁrst-line
AED in brain tumor patients, and conversion of PHT
therapy to LEV monotherapy has not been studied.
Therefore, we prospectively studied the safety and feasi-
bility of converting PHT to LEV monotherapy after
craniotomy for glioma resection in patients with a history
of tumor-related seizures.
Materials and methods
Key patient inclusion criteria for the study included: sei-
zure history attributable to supratentorial glioma, PHT
monotherapy for seizure prophylaxis, planned craniotomy
as standard management, B1 previous resection,[18 years
of age, Karnofosky performance scale of[70, and no other
co-morbidities. Exclusion criteria included: non-glioma
cancer, pregnancy or breast-feeding, seizures unrelated to
the suspected glioma, use of anticonvulsants or AEDs other
than PHT, [1 generalized seizure per day, and prior
interstitial brachytherapy. Preoperative labs were examined
to ensure that patients had a WBC[3.4 9 10
9/l, platelets
[100,000/l, hemoglobin [10 g/dl, INR \1.3, and serum
creatinine\1.5 mg/dl.
We had planned to enroll 60 patients in this study (40
patients in the LEV group, 20 in the PHT group). This study
was designed to be a feasibility study for a potential larger
trial. We designed this trial to have met the ‘‘feasibility’’
requirement if seizure control was no more than 20% points
worse than historical controls. Because of a diminishing
accrual rate, we closed the study after the enrollment of 29
patients. These 29 patients were enrolled over a 13-month
period. After signing an approved Institutional Review
Board consent form, patients were ﬁrst stratiﬁed into two
groups: (1) those with no prior craniotomy, and (2) those
with a history of one craniotomy. Within each stratiﬁcation
group, patients were randomized in a 2:1 ratio to initiate
LEV therapy within 24 h of surgery or to continue PHT
therapy, respectively (Fig. 1). Patients randomized to PHT
therapy had serum levels conﬁrmed to be in the therapeutic
range (10–20 mg/dl) by the ﬁrst postoperative day (POD1);
PHT dosages were adjusted, if necessary. Patient random-
ized to LEV therapy were started on an oral regimen of LEV
1,000 mg twice a day within 24 h of surgery; in these
patients, PHT was tapered off in the following manner:
100% of preoperative PHT regimen on POD0, 75% of PHT
regimen on POD1, 50% of PHT regimen on POD2, and
PHT therapy was discontinued on POD3.
Patients were to be followed postoperatively for
6 months, during which their medical charts were reviewed
and two standardized telephone surveys were conducted at
*3-month intervals. Patients were provided with seizure
diaries and a 24-h pager number to alert study personnel of
any seizures or AED-related SEs. Seizure frequency data
were based on patient-initiated contact of study personnel
(through use of the 24-h pager), the telephone surveys, and
review of medical charts. The primary end point was the
proportion of patients who were seizure free 6 months after
tumor resection. Data on AED-related SEs were collected
with use of the telephone survey speciﬁcally addressing the
SEs listed in Table 3.
Results
Characteristics of the study population are summarized in
Table 1. Although there were some demographic differ-
ences between the two treatment groups, the majority of
the study patients were male, suffered from generalized
seizures, were diagnosed with glioblastoma, and all
underwent craniotomy at the start of the study. One LEV
subject died of the primary pathology before the ﬁrst
evaluation. Four other LEV subjects were withdrawn from
the study by other physicians who preferred different
AEDs; one patient was withdrawn by the neurosurgeon
because the patient was a participant in another neuro-
oncology trial, and PHT was the standard anticonvulsant in
that study; the other three patients were withdrawn from
this study by the neurosurgeon because of a personal
preference for PHT as the anticonvulsant. One PHT subject
could not be located after hospital discharge.
Fifteen patients in the LEV group and eight patients in
the PHT group were assessed for the primary end point of
seizure-freedom at 6 months (Table 2). Thirteen LEV
patients (87%) were free from seizure compared with six
PHT patients (75%). During the study period, all patients
with follow-up were at least Engel Class 2 (rare seizures).
Of the two patients who experienced rare seizures in the
LEV group, one patient had stopped taking LEV, and this
patient did not suffer additional seizures after resuming
therapy; the other patient achieved seizure control with an
increased dosage of LEV (1,500 mg twice a day). Most
(11/15) LEV patients remained on the initial dose of
1,000 mg twice a day. Three LEV patients were able to
lower their dosage to 500 mg twice a day without com-
promising their complete seizure control. PHT dosages
were between 300 and 400 mg per day given as single
dose. No patient required hospitalization for seizures or
seizure control.
Table 3 shows the SEs reported in the telephone ques-
tionnaires administered *3 and 6 months after surgery.
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groups in terms of SEs was difﬁculty with coordination: no
patient in the LEV group reported this difﬁculty, compared
to 4 (57%) and 2 (29%) of the PHT group at 3 and
6 months, respectively. The one patient taking LEV
1,500 mg twice a day did not report more SEs than those
taking 500 mg twice a day, suggesting that LEV dosage
does not correlate with increased SEs. No SEs in any study
patient resulted in a hospitalization or withdrawal from
study.
Discussion
An ideal AED for brain tumor patients would be one that
has few SEs and does not interfere with medications
commonly used in brain tumor treatment. While PHT
is very commonly used for seizure control in brain
tumor patients, it has many undesirable pharmacological
qualities. PHT induces the metabolism of the steroid
dexamethasone [11, 13], and dexamethasone decreases
PHT serum levels [22]. Certain chemotherapeutic agents
Fig. 1 Schematic showing trial design. Patients in the LEV treatment arm (left) were tapered off of PHT therapy over the course of 3 days. See
materials and methods for details
J Neurooncol (2009) 93:349–354 351
123also lower PHT levels [12], and, vice versa, PHT can
accelerate the metabolism of a variety of chemotherapy
drugs including nitrosoureas, paclitaxel, 9-aminocampto-
thecin, thiotepa, topotecan, and irinotecan ([1, 14] and
references therein). In terms of SEs, PHT adversely affects
cognition [23, 24], which is often already depressed in
brain tumor patients. Furthermore, brain tumor patients
taking PHT are at increased risk of drug rashes [25],
including Stevens-Johnson syndrome [26], an immune-
mediated rash associated with severe morbidity and death.
Because LEV does not have any signiﬁcant drug inter-
actions, this AED poses fewer complications for the
pharmacotherapy of brain tumors. A retrospective study of
34 patients with primary brain tumors suggested that LEV
is effective and well tolerated for tumor-related seizure
control, especially as add-on therapy to other AEDs [19].
Prospectively, LEV has been studied as add-on therapy for
seizure control in brain tumor patients. In a cohort of 25
patients with primary brain tumors, Wagner et al. [21]
found that add-on LEV reduced seizure frequency by more
than 50% in 13 of the patients who experienced persistent
seizures. Maschio et al. [20] prospectively followed 19
patients with primary brain tumors who had LEV added to
existing AED therapy on account of persisting seizures; in
that study, 14 patients had improvement in seizure control.
There have been no reports of serious SEs of LEV therapy
in any of the studies of brain tumor patients to date. For the
reasons described above, safe conversion of PHT to LEV
monotherapy may provide signiﬁcant clinical advantages
for the post-surgical medical treatment of primary brain
tumors.
Table 1 Characteristics of
study population
DNET dysembryoplastic
neuroepithelial tumor; PXA
pleomorphic
xanthoastrocytoma; WHO
World Health Organization
(brain tumor grading scale)
Total patients
n (%)
LEV patients
n (% of arm)
PHT patients
n (% of arm)
Subjects enrolled 29 (100) 20 (69) 9 (31)
Subjects with primary end-point follow-up 23 (79) 15 (75) 8 (89)
Demographics
Female 6 (26) 6 (40) 0
Median age (range) 45 (20–83) 46 (20–56) 39 (32–83)
Seizure type at presentation
Simple partial 7 (30) 6 (40) 1 (13)
Complex partial 5 (22) 1 (7) 4 (50)
Generalized 11 (48) 8 (53) 3 (38)
Surgery
Craniotomy before study surgery 7 (30) 4 (27) 3 (38)
Craniotomy for study
Gross total resection 13 (56) 10 (67) 3 (38)
Subtotal resection 10 (43) 5 (33) 5 (63)
Final tumor pathology
WHO grade 1
DNET 1 (4) 1 (7) 0
WHO grade 2
Astrocytoma 3 (13) 2 (13) 1 (13)
Oligodendroglioma 2 (9) 1 (7) 1 (13)
PXA 1 (4) 1 (7) 0
WHO grade 3
Astrocytoma 4 (17) 4 (27) 0
Oligodendroglioma 1 (4) 0 1 (13)
Oligoastrocytoma 2 (9) 1 (7) 1 (13)
WHO grade 4
Glioblastoma 9 (39) 6 (40) 3 (38)
Table 2 Postoperative seizure status at 6 months
Seizure status (Engel score) LEV patients
n (%)
PHT patients
n (%)
n at follow-up 15 8
Class 1: seizure free 13 (87) 6 (75)
Class 2: rare seizures 2 (12) 2 (25)
Class 3: meaningful improvement 0 0
Class 4: no improvement 0 0
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similar proportions of seizure-free patients (87% and 75%,
respectively) at 6 months of follow-up. These seizure
control rates are in line with those observed in a retro-
spective analysis of low grade glioma patients treated at
this institution; of 253 patients who had tumor-related
seizures, 169 (67%) were seizure-free 6 months after cra-
niotomy for tumor resection [8]. Thus, LEV and PHT
groups had expected levels of seizure control. Furthermore,
no patient in our study had seizures refractory to either
LEV or PHT therapy.
LEV and PHT were both well tolerated in our study
population. Although difﬁculty with coordination is a
potential SE for both LEV and PHT, no patient in the
LEV study group (0/15) admitted to experiencing this
difﬁculty while more than half of the PHT group (4/7) at
3 months reported this SE. Other known LEV SEs are
somnolence and behavioral abnormalities. Both PHT and
LEV groups had similar proportions of patients reporting
somnolence. One subject in the LEV group reported
feeling unusually hostile towards others after starting
LEV therapy; however, this behavioral change did not
require the discontinuation of LEV. No PHT study subject
admitted to experiencing any emotional instability at any
time point. In placebo-controlled trials of LEV for partial-
onset epilepsy, LEV was associated with a 0.7% incidence
of psychosis as compared to 0.2% for placebo patients.
Although Maschio et al. reported that there were no LEV-
related SEs observed in their study of primary brain tumor
patients, Wagner et al. did report one patient in their study
of 26 who developed a psychosis 4 weeks after initiating
LEV therapy which resulted in discontinuation of this
AED. Given the report of psychosis in Wagner et al. and
our ﬁndings of emotional instability in up to 13% of our
LEV group as compared to none in the PHT group
(Table 2), we suggest that it would be important to eval-
uate brain tumor patients on LEV therapy for potential
behavioral problems.
Our pilot data presented here suggest that it is safe and
feasible to switch from PHT to LEV monotherapy after
craniotomy for glioma-related seizures. Due to the small
size of our study, the data presented here cannot serve as
an ofﬁcial endorsement of LEV efﬁcacy in this patient
population. A large-scale, double-blinded, randomized
controlled trial is warranted to compare PHT and LEV for
seizure control equivalence and SE proﬁles.
Table 3 Results of patient
questionnaire on SEs
3 months postoperation 6 months postoperation
LEV patients
n (%)
PHT patients
n (%)
LEV patients
n (%)
PHT patients
n (%)
Number of respondents 15 7 15 7
Questions regarding potential SEs
Have you been experiencing any of the following symptoms?
Dizziness 1 (7) 0 0 1 (14)
Headache 1 (7) 1 (14) 1 (7) 1 (14)
Difﬁculty with coordination 0 4 (57) 0 2 (29)
Excessive sleepiness 3 (20) 2 (29) 3 (20) 2 (29)
Enlarged gums 0 0 0 0
Depression 1 (7) 1 (14) 1 (7) 1 (14)
Difﬁculty sleeping 5 (33) 1 (14) 6 (40) 3 (43)
Itchiness 0 1 (14) 0 0
Nausea 0 0 0 0
Vomiting 0 0 0 0
Tingling, ‘‘pins and needles’’ sensation 0 1 (14) 0 0
Nervousness 1 (7) 1 (14) 0 0
Emotional instability 2 (13) 0 1 (7) 0
Slurred speech 1 (7) 0 2 (13) 0
Lack of Energy or Strength 4 (27) 4 (57) 3 (20) 3 (43)
Constipation 0 1 (14) 0 0
Difﬁculty keeping balance 0 0 0 0
Rash 0 0 0 0
Have you been experiencing any other SEs
that you attribute to your medication?
3 (20) 2 (29) 2 (13) 2 (29)
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